본문 바로가기
KERD
논문KCI 등재

CD36 (SR-B2) as a Target to Treat Lipid Overload-Induced Cardiac Dysfunction

Jan F.C. Glatz|Joost J.F.P. Luiken|Miranda Nabben
한국지질동맥경화학회 (The Korean Society of Lipidology and Atherosclerosis)|2020.01|지질·동맥경화학회지 (Journal of Lipid and Atherosclerosis)|제9권 제1호|pp. 66-78|DOI 10.12997/jla.2020.9.1.66

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

CardiomyopathyCardiac functionCluster of differentiation 36Scavenger receptor B2Lipid overload

초록

The heart faces the challenge of adjusting the rate of fatty acid uptake to match myocardial demand for energy provision at any given moment, avoiding both too low uptake rates, which could elicit an energy deficit, and too high uptake rates, which pose the risk of excess lipid accumulation and lipotoxicity. The transmembrane glycoprotein cluster of differentiation 36 (CD36), a scavenger receptor (B2), serves many functions in lipid metabolism and signaling. In the heart, CD36 is the main sarcolemmal lipid transporter involved in the rate-limiting kinetic step in cardiac lipid utilization. The cellular fatty acid uptake rate is determined by the presence of CD36 at the cell surface, which is regulated by subcellular vesicular recycling from endosomes to the sarcolemma. CD36 has been implicated in dysregulated fatty acid and lipid metabolism in pathophysiological conditions, particularly high-fat diet-induced insulin resistance and diabetic cardiomyopathy. Thus, in conditions of chronic lipid overload, high levels of CD36 are moved to the sarcolemma, setting the heart on a route towards increased lipid uptake, excessive lipid accumulation, insulin resistance, and eventually contractile dysfunction. Insight into the subcellular trafficking machinery of CD36 will provide novel targets to treat the lipid-overloaded heart. A screen for CD36-dedicated trafficking proteins found that vacuolar-type H+-ATPase and specific vesicle-associated membrane proteins, among others, were uniquely involved in CD36 recycling. Preliminary data suggest that these proteins may offer clues on how to manipulate myocardial lipid uptake, and thus could be promising targets for metabolic intervention therapy to treat the failing heart.

Abstract

The heart faces the challenge of adjusting the rate of fatty acid uptake to match myocardial demand for energy provision at any given moment, avoiding both too low uptake rates, which could elicit an energy deficit, and too high uptake rates, which pose the risk of excess lipid accumulation and lipotoxicity. The transmembrane glycoprotein cluster of differentiation 36 (CD36), a scavenger receptor (B2), serves many functions in lipid metabolism and signaling. In the heart, CD36 is the main sarcolemmal lipid transporter involved in the rate-limiting kinetic step in cardiac lipid utilization. The cellular fatty acid uptake rate is determined by the presence of CD36 at the cell surface, which is regulated by subcellular vesicular recycling from endosomes to the sarcolemma. CD36 has been implicated in dysregulated fatty acid and lipid metabolism in pathophysiological conditions, particularly high-fat diet-induced insulin resistance and diabetic cardiomyopathy. Thus, in conditions of chronic lipid overload, high levels of CD36 are moved to the sarcolemma, setting the heart on a route towards increased lipid uptake, excessive lipid accumulation, insulin resistance, and eventually contractile dysfunction. Insight into the subcellular trafficking machinery of CD36 will provide novel targets to treat the lipid-overloaded heart. A screen for CD36-dedicated trafficking proteins found that vacuolar-type H+-ATPase and specific vesicle-associated membrane proteins, among others, were uniquely involved in CD36 recycling. Preliminary data suggest that these proteins may offer clues on how to manipulate myocardial lipid uptake, and thus could be promising targets for metabolic intervention therapy to treat the failing heart.

참고문헌 (49)

  1. Longo M, "Adipose tissue dysfunction as determinant of obesity-associated metabolic complications", Int J Mol Sci, 20, pp.E2358~ (2019)
  2. Sharma S, "Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart", FASEB J, 18, pp.1692~1700 (2004)
  3. Boudina S, "Diabetic cardiomyopathy, causes and effects", Rev Endocr Metab Disord, 11, pp.31~39 (2010)
  4. Zlobine I, "Lipotoxicity in obesity and diabetes-related cardiac dysfunction", Biochim Biophys Acta, 1861, pp.1555~1568 (2016)
  5. Stanley WC, "Myocardial substrate metabolism in the normal and failing heart", Physiol Rev, 85, pp.1093~1129 (2005)
  6. Glatz JF, "From fat to FAT(CD36", SR-B2) : understanding the regulation of cellular fatty acid uptake, 2017, pp.136, 21~26
  7. Glatz JFC, "Dynamic role of the transmembrane glycoprotein CD36(SR-B2)in cellular fatty acid uptake and utilization", J Lipid Res, 59, pp.1084~1093 (2018)
  8. Prabhudas M, "Standardizing scavenger receptor nomenclature", J Immunol, 192, pp.1997~2006 (2014)
  9. Stremmel W, "Identification, isolation, and partial characterization of a fatty acid binding protein from rat jejunal microvillous membranes", J Clin Invest, 75, pp.1068~1076 (1985)
  10. Kazantzis M, "Fatty acid transport proteins, implications in physiology and disease", Biochim Biophys Acta, 1821, pp.852~857 (2012)
  11. Hsieh FL, "The structural basis for CD36 binding by the malaria parasite", Nat Commun, 7, pp.12837~ (2016)
  12. Hamilton JA, "New insights into the roles of proteins and lipids in membrane transport of fatty acids", Prostaglandins Leukot Essent Fatty Acids, 77, pp.355~361 (2007)
  13. Luiken JJ, "Electrostimulation enhances FAT", CD36-mediated long-chain fatty acid uptake by isolated rat cardiac myocytes, 2001, pp.281, E704~E712
  14. Luiken JJ, "Contraction-induced fatty acid translocase", CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling, 2003, pp.52, 1627~1634
  15. Bonen A, "Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid translocase", J Biol Chem, 275, pp.14501~14508 (2000)
  16. van Oort MM, "Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that of GLUT4", Biochim Biophys Acta, 1781, pp.61~71 (2008)
  17. Klip A, "Thirty sweet years of GLUT4", J Biol Chem, 294, pp.11369~11381 (2019)
  18. Glatz JF, "Membrane fatty acid transporters as regulators of lipid metabolism : implications for metabolic disease", Physiol Rev, 90, pp.367~417 (2010)
  19. Habets DD, "AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36", Biochem Biophys Res Commun, 355, pp.204~210 (2007)
  20. Kerner J, "Fatty acid import into mitochondria", Biochim Biophys Acta, 1486, pp.1~17 (2000)
  21. Glatz JFC, "Cardiac energy metabolism in health and disease", pp.49~67 (2014), Springer Science Inc
  22. Luiken JJ, "Etomoxir-induced partial carnitine palmitoyltransferase-I(CPT-I)inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates", Biochem J, 419, pp.447~455 (2009)
  23. Ouwens DM, "Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy", Arch Physiol Biochem, 113, pp.76~86 (2007)
  24. Bonen A, "Extremely rapid increase in fatty acid transport and intramyocellular lipid accumulation but markedly delayed insulin resistance after high fat feeding in rats", Diabetologia, 58, pp.2381~2391 (2015)
  25. Shulman GI, "Cellular mechanisms of insulin resistance", J Clin Invest, 106, pp.171~176 (2000)
  26. Ouwens DM, "Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification", Diabetologia, 50, pp.1938~1948 (2007)
  27. Angin Y, "CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes", Biochem J, 448, pp.43~53 (2012)
  28. Steinbusch LK, "Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice", Am J Physiol Endocrinol Metab, 301, pp.E618~E627 (2011)
  29. Sung MM, "Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction", J Mol Med(Berl), 89, pp.459~469 (2011)
  30. Zhu B, "Lipid oversupply induces CD36 sarcolemmal translocation via dual modulation of PKCζ and TBC1D1 : an early event prior to insulin resistance", Theranostics, 10, pp.1332~1354 (2020)
  31. Silverstein RL, "CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior", Sci Signal, 2, pp.re3~ (2009)
  32. Chi RJ, "Biogenesis of endosome-derived transport carriers", Cell Mol Life Sci, 72, pp.3441~3455 (2015)
  33. Glatz JF, "Regulation of the subcellular trafficking of CD36, a major determinant of cardiac fatty acid utilization", Biochim Biophys Acta, 1861, pp.1461~1471 (2016)
  34. Steinbusch LK, "Differential regulation of cardiac glucose and fatty acid uptake by endosomal pH and actin filaments", Am J Physiol Cell Physiol, 298, pp.C1549~C1559 (2010)
  35. Liu Y, "Palmitate-induced vacuolar-type H+-ATPase inhibition feeds forward into insulin resistance and contractile dysfunction", Diabetes, 66, pp.1521~1534 (2017)
  36. Kane PM, "Targeting reversible disassembly as a mechanism of controlling V-ATPase activity", Curr Protein Pept Sci, 13, pp.117~123 (2012)
  37. McGuire C, "Regulation of V-ATPase activity", Front Biosci(Landmark Ed), 22, pp.609~622 (2017)
  38. Bond S, "The Ras", cAMP, J Biol Chem, pp.2008, 283[DOI]
  39. Schwenk RW, "Requirement for distinct vesicle-associated membrane proteins in insulin-and AMP-activated protein kinase(AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes", Diabetologia, 53, pp.2209~2219 (2010)
  40. Sabra MM, "Vesicle-associated membrane protein 4, a positional candidate gene on 1q24-q25, is not associated with type 2 diabetes in the Old Order Amish", Mol Genet Metab, 85, pp.133~139 (2005)
  41. Geraets IM, "Pivotal role of membrane substrate transporters on the metabolic alterations in the pressure-overloaded heart", Cardiovasc Res, 115, pp.1000~1012 (2019)
  42. Glatz JFC, "Re-balancing cellular energy substrate metabolism to mend the failing heart", Biochim Biophys Acta Mol Basis Dis (2020)
  43. Luiken JJ, "Post-translational modifications of CD36(SR-B2) : implications for regulation of myocellular fatty acid uptake", Biochim Biophys Acta, 1862, pp.2253~2258 (2016)
  44. Son NH, "Endothelial cell CD36 optimizes tissue fatty acid uptake", J Clin Invest, 128, pp.4329~4342 (2018)
  45. Keizer HA, "Subcellular immunolocalisation of fatty acid translocase(FAT)", CD36 in human type-1 and type-2 skeletal muscle fibres, 2004, pp.121, 101~107
  46. Puchalska P, "Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics", Cell Metab, 25, pp.262~284 (2017)
  47. Aquilani R, "Plasma amino acid abnormalities in chronic heart failure. Mechanisms, potential risks and targets in human myocardium metabolism", Nutrients, 9, pp.E1251~ (2017)
  48. Chen L, "Metabolic remodeling of substrate utilization during heart failure progression", Heart Fail Rev, 24, pp.143~154 (2019)
  49. Wende AR, "Metabolic origins of heart failure", JACC Basic Transl Sci, 2, pp.297~310 (2017)

이 간행물의 다른 논문 (15건)

Effects of Statins for Primary Prevention in the Elderly: Recent Evidence김규, 이상학pp. 1-7mTOR-coordinated Post-Transcriptional Gene Regulations: from Fundamental to Pathogenic Insights용정식, Hsin-Sung Yehpp. 8-22Sphingolipid Mediators of Myocardial PathologyAnna Kovilakath, L. Ashley Cowartpp. 23-49Ceramides: Nutrient Signals that Drive HepatosteatosisScott A. Summerspp. 50-65Cellular Senescence in Arterial DiseasesTohru Minamino, Ippei Shimizupp. 79-91
원문 보기